Cambridge Healthtech Institute's 17th Annual
Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Novel and Synergistic Combinations
12 November 2025 ALL TIMES WET (GMT/UTC)
A rapidly growing repertoire of multispecific antibodies is being created with greater functionality and efficacy than ever before and has become the dominant and preferred modality in the antibody drug marketplace. Cambridge Healthtech Institute's Seventeenth Annual Advancing Multispecific Antibodies and Combination Therapy track at PEGS Europe will bring together the leading players in the field to disclose the latest preclinical and clinical results of these novel constructs and assess their viability. Best practices for translation and optimization of candidates will be shared through case studies and examples.
Scientific Advisory Board
Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC and Entrepreneur in Residence, FairJourney Biologics
Paul Parren, PhD, CSO, Gyes; Professor, Molecular Immunology, Leiden University Medical Center
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.
Leendert A. Trouw, PhD, Professor, Department of Immunology, Leiden University Medical Center
Recommended Short Course*
Monday, 4 November, 14:00 – 17:00
SC3: Developability of Bispecific Antibodies
*Separate registration required. See short courses page for details. All short courses take place in-person only.